Clostridium difficile infection
ICD-10 A04.7 · ICD-11 1A04

Treatment of Initial Non-Severe CDI: WBC Below 15,000 cells/mm³ with Creatinine at or Below 1.5 mg/dL

This protocol applies to patients presenting with a first episode of Clostridioides difficile infection whose laboratory values confirm non-severe disease — defined by a white blood cell count below 15,000 cells/mm³ and a serum creatinine of 1.5 mg/dL or below.

Clinical scenario

At the time of diagnosis, a WBC at or above 15,000 cells/mm³ or a serum creatinine above 1.5 mg/dL each predict unfavorable outcomes and indicate severe CDI. When both values fall below those thresholds — WBC under 15,000 cells/mm³ and creatinine 1.5 mg/dL or below — the episode is classified as non-severe, guiding a distinct treatment pathway.

Treatment approach

The structured protocol for this patient population specifies antibiotic options — including approaches based on vancomycin or fidaxomicin — with selection guided by prior treatment history. The complete regimen, decision criteria, and sequencing are available in the full protocol.

Treatment goal

Sustained symptomatic cure: initial resolution of diarrhea with no evidence of recurrence of diarrhea due to CDI.

Instant Access to Structured Evidence-Based Regimens

References

  1. We recommend that oral vancomycin 125 mg 4 times daily for 10 days be used to treat an initial episode of nonsevere CDI (strong recommendation, low quality of evidence).
  2. We recommend the following criteria, which are predictive of unfavorable outcomes, be used to classify severe C. difficile infection at the time of diagnosis: white blood cell (WBC) ≥15,000 cells/mm³ or serum creatinine >1.5 mg/dL.
  3. We suggest tapering/pulsed-dose vancomycin for patients experiencing a first recurrence after an initial course of fidaxomicin, vancomycin, or metronidazole (strong recommendation, very low quality of evidence).
  4. We recommend fidaxomicin for patients experiencing a first recurrence after an initial course of vancomycin or metronidazole (conditional recommendation, moderate quality of evidence).
  5. Outcomes of interest in this patient population are sustained symptomatic cure defined as initial resolution of the diarrhea and no evidence of recurrence of diarrhea due to CDI.

DOI: 10.14309/ajg.0000000000001278

View source ↗